Published 2024
| Version v1
Journal article
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
Creators
- Gantzer, Justine
- Toulmonde, Maud
- Séverac, François
- Chamseddine, Ali N.
- Charon-Barra, Celine
- Vinson, Charles
- Hervieu, Alice
- Bourgmayer, Agathe
- Bertucci, François
- Ryckewaert, Thomas
- Valentin, Thibaud
- Firmin, Nelly
- Chaigneau, Loïc
- Bompas, Emmanuelle
- Follana, Philippe
- Rioux-Leclercq, Nathalie
- Soibinet-Oudot, Pauline
- Bozec, Laurence
- Le Loarer, François
- Weingertner, Noëlle
- Chevreau, Christine
- Duffaud, Florence
- Blay, Jean-Yves
- Kurtz, Jean-Emmanuel
- Schöffski, Patrick
- Brahmi, Mehdi
- Malouf, Gabriel G.
Contributors
Others:
- Institut de Cancérologie de Strasbourg Europe (ICANS)
- Institut Bergonié [Bordeaux] ; UNICANCER
- Les Hôpitaux Universitaires de Strasbourg (HUS)
- Institut Gustave Roussy (IGR)
- Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
- Institut Paoli-Calmettes (IPC) ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
- Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille) ; Université de Lille-UNICANCER
- Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM) ; CRLCC Val d'Aurelle - Paul Lamarque
- Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO) ; UNICANCER
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UniCA)
- Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
- Institut de recherche en santé, environnement et travail (Irset) ; Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Institut Jean Godinot [Reims] ; UNICANCER
- Institut Curie - Saint Cloud (ICSC)
- Centre Léon Bérard [Lyon]
- University Hospitals Leuven [Leuven]
- French Sarcoma Clinical Reference Network; INCA [PRTK-2020-046]
Description
Background: Perivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value.Methods: This retrospective analysis examined clinicopathologic data from patients who had localized PEComa across French Sarcoma Network centers. The authors analyzed 12 clinicopathologic features in a Cox proportional hazard framework to derive a multivariate prognostic risk model for event-free survival (EFS). They built the PEComa prognostic score (PEC-PRO), in which scores ranged from 0 to 5, based on the coefficients of the multivariate model. Three groups were identified: low risk (score = 0), intermediate risk (score = 1), and high risk (score ≥ 2).Results: Analyzing 87 patients who had a median 46-month follow-up (interquartile range, 20-74 months), the median EFS was 96.5 months (95% confidence interval [CI], 47.1 months to not applicable), with 2-year and 5-year EFS rates of 64.7% and 58%, respectively. The median overall survival was unreached, with 2-year and 5-year overall survival rates of 82.3% and 69.3%, respectively. The simplified Folpe classification did not correlate with EFS. Multivariate analysis identified three factors affecting EFS: positive surgical margins (hazard ratio [HR], 5.17; 95% CI, 1.65-16.24; p = .008), necrosis (HR, 3.94; 95% CI, 1.16-13.43; p = .030), and male sex (HR, 3.13; 95% CI, 1.19-8.27; p = 0.023). Four variables were retained in the prognostic model. Patients with low-risk PEC-PRO scores had a 2-year EFS rate of 93.7% (95% CI, 83.8%-100.0%), those with intermediate-risk PEC-PRO scores had a 2-year EFS rate of 67.4% (95% CI, 53.9%-80.9%), and those with high-risk PEC-PRO scores had a 2-year EFS rate of 2.3% (95% CI, 0.0%-18.3%).Conclusions: The PEC-PRO score reliably predicts the risk of postoperative recurrence in patients with localized PEComa. It has the potential to improve follow-up strategies but requires validation in a prospective trial.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04533834
- URN
- urn:oai:HAL:hal-04533834v1
Origin repository
- Origin repository
- UNICA